drugset / Trial / NCT06412458
IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma
Phase 1
Unknown
9 enrolled
Beijing Immunochina Medical Science & Technology Co., Ltd.
Guangdong Provincial People's Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study, a single-center, open, single-dose clinical study, was to evaluate the safety, tolerability, and pharmacokinetic profile of IM83 CAR-T cells in the treatment of patients with relapsed or refractory osteosarcoma
Timeline
- Start
- 2024-06-15
- Primary completion
- 2025-06-15
- Completion
- 2026-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IM83 CAR-T Cells | Cell therapy | 5e+08 cells | — |
| Subject | IM83 CAR-T Cells | Cell therapy | 1e+09 cells | — |
| Subject | IM83 CAR-T Cells | Cell therapy | 2e+09 cells | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |